基本信息
views: 70
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Ismael Samudio obtained his Ph.D. in genetics from Texas A&M University and received postdoctoral training in pharmacology and toxicology at the Institute of Biotechnology in Houston. In 2004 he joined the Section of Molecular Hematology at MD Anderson Cancer Center (MDACC) where he led and supported various clinical and pre-clinical studies on the anti-leukemic and anti-tumor effects of various targeted agents, including the MDM-2 inhibitor Nutlin 3a (Idasanutlin) and the orally active bcl-2 inhibitors ABT-737, ABT-199, and the recently approved Navitoclax. While at MD Anderson, Ismael also conducted seminal work demonstrating that the Warburg effect in leukemias was a consequence of uncoupled mitochondrial respiration resulting in the reliance of leukemic stem cells on fatty acid oxidation for survival and chemoresistance. In addition, in collaboration with Dr. Michael Andreeff and Dr. Frank Marini, he demonstrated the therapeutic efficacy of gene-modified mesenchymal stromal cells in animal models of pancreatic and ovarian cancer.
In 2015, Ismael was recruited to the Centre for Drug Research and Development (CDRD) to lead a nascent immunotherapy initiative, eventually becoming director of the Biologics Division where he led the discovery & development of several novel anti-tumor biotherapeutics of various formats, including CAR-T, antibody drug-conjugates (ADC), and functional antibodies. In 2019 he became senior director of research for Virogin biotech, where he was responsible for overseeing the development of the oncolytic virotherapy pipeline and the analysis of exploratory endpoints from the company’s first clinical trial of a novel attenuated herpes virus simplex expressing IL12, IL15, and a PD-L1 blocking peptide. Most recently, Ismael joined Notch Therapeutics as the senior director of Cancer Biology & Translational Sciences where he oversees the discovery pipeline of cellular therapeutics for various human diseases. Ismael has published over 70 peer reviewed articles and various book chapters on the use of small molecules, cellular therapeutics, and immunotherapy strategies for the treatment of cancer, and is coinventor on multiple therapeutic patents.
Research Interests
Papers共 167 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
MOLECULAR THERAPY-ONCOLYTICS (2023): 334-348
crossref(2023)
Cancer Researchno. 13_Supplement (2021): 1913-1913
Cited0Views0Bibtex
0
0
CANCER MEDICINEno. 9 (2020): 2943-2959
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn